With embryonic stem cells in clinical trials in the U.S. and the U.K., France looks to keep up.
Susan YoungFollow @twitterapi
I’m the biomedicine editor for MIT Technology Review. I look for stories where technology stands to improve human health or advance our understanding of the human condition.
I joined MIT Technology Review in March 2012 after a brief stint in the Washington, D.C., news bureau of the scientific journal Nature. Before I ventured to the East Coast, I spent several years in the San Francisco Bay Area as a doctoral student in molecular biology and one whirlwind year in science-writing boot camp in Santa Cruz.
In California, I wrote for the Stanford University press offices, the Multiple Sclerosis Discovery Forum, and the Salinas Californian newspaper. I grew up in a small town in eastern Texas, surrounded by bird song, rolling cattle fields, and lanky pine trees. When I’m not exploring health tech, you will probably find me cooking or giggling over an exceptional LOLcat.
Susan Young's Stories
DNA analysis continues its baby boom.
Patients with blindness caused by retinitis pigmentosa can now get a light-detecting microchip implanted in one of their retinas.
Genetic material suitable for sequencing could persist for as many as one million years, predict scientists.
A biomarker could cut the trial-and-error of finding a patient's best therapy.
A common framework for analyzing and sharing genomic information could speed medical progress.
A large genetic study finds gene variants with a subtle effect on scholastic achievement.
Scientists produced embryonic stem cells from the DNA of one person combined with a human donor egg.
Researchers attach "viral hitmen" to surfaces to demonstrate a possible antibacterial defense for catheters and other medical devices.
A mixed-antibody treatment does not protect patients from cognitive decline.